Recent developments highlight strong commercial performance with significant sales growth and positive adjusted EBITDA, ongoing clinical and regulatory progress, and strategic partnerships supporting market expansion.

• Fennec Pharmaceuticals reported a 78% surge in Q2 sales and adjusted EBITDA turned positive, indicating improving financial performance [N2].
• The company announced Q2 earnings and revenue results exceeding prior expectations, reflecting operational progress [N3].
• Fennec's PEDMARK® push targets a larger Adolescent and Young Adult (AYA) market following a record quarter, expanding potential patient reach [N6].
• Fennec's Q1 2026 earnings call provided insights into commercial execution and clinical development activities [N7].
• The company launched an investigator-sponsored trial of PEDMARK® in AYA and adult cancer patients to explore broader clinical applications [N7].
• Fennec entered into a settlement and license agreement with Cipla to resolve patent litigation, delaying generic entry until September 1, 2033 [S1].

Fennec's product PEDMARK® addresses a significant unmet medical need by reducing the risk of irreversible hearing loss in pediatric cancer patients treated with cisplatin. The company's established patent portfolio and regulatory exclusivities provide a foundation for sustained market exclusivity. The licensing partnership with Norgine enables access to European and other international markets, while ongoing investigator-initiated studies and positive clinical data in Japan support potential geographic expansion. Recent financial results showing strong sales growth and positive adjusted EBITDA indicate improving commercial traction. The patient access program and specialized sales force support adoption in the U.S. market.

Fennec faces risks related to intellectual property challenges, including potential patent invalidation or infringement claims that could affect exclusivity and market position. The settlement with Cipla, while delaying generic entry, still allows for potential earlier competition under certain conditions. Market adoption depends on continued physician acceptance and reimbursement, which may be influenced by competitive therapies or changes in treatment protocols. Regulatory approvals and commercialization in new markets such as Japan involve uncertainties. The company's financial performance is sensitive to sales execution and market penetration, and failure to achieve milestone payments from licensing partners could impact revenue.

Fennec's competitive moat is anchored by its FDA and European Commission approvals for PEDMARK®, the only approved therapy for preventing cisplatin-induced ototoxicity in pediatric patients. The company holds multiple patents covering the product's formulation and methods of use, with patent protection extending through 2039. The settlement agreement with Cipla delays generic competition in the U.S. until 2033, enhancing exclusivity. Orphan Drug Exclusivity provides additional market protection until 2029. The licensing agreement with Norgine for Europe and other territories leverages established commercialization capabilities. These intellectual property rights, regulatory exclusivities, and strategic partnerships collectively create barriers to entry and support market position.

• Intellectual Property Risks: Fennec's patents covering PEDMARK® may be challenged, invalidated, or circumvented, which could reduce exclusivity and allow generic competition. Litigation to defend patents can be costly and divert management attention [S1].
• Generic Competition: Despite the settlement with Cipla delaying generic entry until 2033, there remains a risk of earlier market entry under certain circumstances, which could impact revenues [S1].
• Regulatory and Commercial Risks: Approval and commercialization in new markets such as Japan depend on ongoing clinical trials and regulatory discussions. Market adoption requires physician acceptance, payer reimbursement, and effective sales execution [S1][S2].
• Financial Risks: The company's revenue depends on sales growth and milestone payments from licensing partners. Failure to achieve these could affect financial results. Operating expenses and cash flow management remain important [S2].

• Fennec Pharmaceuticals Inc. is a commercial stage specialty pharmaceutical company focused on preventing cisplatin-induced ototoxicity (CIO) with an FDA and European Commission approved product, PEDMARK® (sodium thiosulfate injection) in the U.S. and PEDMARQSI® in Europe and other territories [S1][S2].
• PEDMARK® is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors [S1].
• PEDMARK® demonstrated approximately 50% relative reduction in incidence of cisplatin-induced hearing loss in clinical studies without compromising antitumor efficacy [S1].
• Fennec has an exclusive licensing agreement with Norgine for commercialization of PEDMARQSI® in Europe, Australia, and New Zealand, with upfront payments of approximately $43 million and potential milestone and royalty payments up to $230 million and mid-twenties percentage royalties respectively [S1][S2].
• Norgine launched PEDMARQSI® in the U.K. and Germany in 2025 with additional launches planned in 2026 and beyond [S1][S2].
• Fennec sells PEDMARK® in the U.S. through a field force including Territory Managers and medical science liaisons, supported by a patient access program called Fennec HEARS® that provides financial and product access support [S1][S2].
• Fennec received Orphan Drug Exclusivity for PEDMARK® in January 2023, providing seven years of market exclusivity in the U.S. until September 20, 2029 [S1].
• Fennec holds six patents listed in the FDA Orange Book covering PEDMARK®, with expiration dates extending to 2039, including patents covering formulation and methods of use [S1].
• Fennec settled patent litigation with Cipla Limited and Cipla USA, resulting in Cipla agreeing not to market a generic version of PEDMARK® in the U.S. until September 1, 2033, or earlier under certain conditions [S1].
• Fennec supports investigator-initiated clinical studies to expand PEDMARK® use in additional tumor types and patient populations, including a positive investigator-initiated trial in Japan (STS-J01) with plans for regulatory registration and partnering discussions [S1][S2].
• Fennec estimates approximately 11,400 pediatric patients with localized, non-metastatic solid tumors in the U.S. and Europe annually, with about 3,400 cisplatin-treated pediatric patients in these markets [S1].
• The Adolescent and Young Adult (AYA) oncology segment includes approximately 51,282 new solid tumor cases annually in the U.S., with about 25,536 cisplatin-treated patients, representing a potential market expansion [S1].
• Cisplatin-induced ototoxicity is a significant unmet medical need, with high incidence rates of permanent hearing loss in treated patients, leading to long-term developmental and economic burdens [S1].
• Fennec's Q2 2026 sales surged 78% with adjusted EBITDA turning positive, indicating improving commercial performance [N2].
• Fennec reported net income of $1.97 million and revenue of $17.87 million for the quarter ended June 30, 2026, with basic EPS of $0.06 and diluted EPS of $0.05 [S2].
• As of June 30, 2026, Fennec had $41.25 million in cash and cash equivalents, current assets of $72.5 million, current liabilities of $12.39 million, a current ratio of 5.85, and a cash ratio of 3.33, indicating strong liquidity [S2].